Modality
mAb
MOA
AuroraAi
Target
IL-13
Pathway
Complement
Ewing Sarcoma
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Sep 2030
Phase 1Current
NCT07267490
373 pts·Ewing Sarcoma
2019-04→2030-09·Not yet recruiting
NCT05752393
1,497 pts·Ewing Sarcoma
2018-02→2030-06·Terminated
1,870 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-06-234.2y awayPh2 Data· Ewing Sarcoma
2030-09-254.5y awayPh2 Data· Ewing Sarcoma
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
P1/2
Not yet…
Catalysts
Ph2 Data
2030-06-23 · 4.2y away
Ewing Sarcoma
Ph2 Data
2030-09-25 · 4.5y away
Ewing Sarcoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07267490 | Phase 1/2 | Ewing Sarcoma | Not yet recr... | 373 | EDSS |
| NCT05752393 | Phase 1/2 | Ewing Sarcoma | Terminated | 1497 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 |